Qualigen Therapeutics Inc (QLGN)
4.177
+0.25
(+6.28%)
USD |
NASDAQ |
Nov 13, 16:00
4.02
-0.16
(-3.75%)
After-Hours: 20:00
Qualigen Therapeutics Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2022 | 0.0649 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.001 |
| September 30, 2020 | -0.3279 |
| June 30, 2020 | -0.1008 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.3279
Minimum
Sep 2020
0.0649
Maximum
Jun 2022
-0.0454
Average
--
Median
Jun 2021
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.4322 |
| IGC Pharma Inc | 0.0173 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Protalix BioTherapeutics Inc | 0.7145 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.5344M |
| Total Liabilities (Quarterly) | 4.812M |
| Shareholders Equity (Quarterly) | -4.278M |